Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04699812 · ClinicalTrials.gov registry record · NA
Atrial Fibrillation Algorithms Clinical Validation Study
A NA study, sponsored by Apple.
- Completed
- Registry status
- NA
- Development phase
- 573
- Enrollment target
NCT04699812: Completed NA study, sponsored by Apple.
NCT04699812 is a NA study that has completed, run by Apple. The registered enrollment target is 573 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04699812, a NA study, has completed, sponsored by Apple.
- COMPLETED
- Registry status
- NA
- Development phase
- 573 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the performances of investigational Irregular Rhythm Notification Feature (version 2.0) and Atrial Fibrillation History Feature algorithms.
Primary Outcome
Sensitivity of the irregular rhythm notification for the identification of persons with AF by 13-day ambulatory ECG, with AF defined as at least 30 seconds of AF by ambulatory ECG. Sensitivity is defined as the percentage of subjects exhibiting AF on the ambulatory ECG who also received an irregular rhythm notification concordant with at least one episode of AF.
Interventions
- DEVICE ELECTROCARDIOGRAM (ECG) PATCH WEAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 573 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2021-12-17 |
| Phase | NA |
What the finished NCT04699812 record still lists
NCT04699812 is an interventional study that assigns participants to a tested intervention. The registered 573 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 1 intervention - of which ELECTROCARDIOGRAM (ECG) PATCH WEAR is the first listed.
NCT04699812 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04699812 about?
NCT04699812 is a clinical study titled "Atrial Fibrillation Algorithms Clinical Validation Study". The purpose of the study is to evaluate the performances of investigational Irregular Rhythm Notification Feature (version 2.0) and Atrial Fibrillation History Feature algorithms.
What is the current status of trial NCT04699812?
This trial is currently completed. It is a NA study. The enrollment target is 573 participants. The study started on 2020-11-16. Estimated completion is 2021-12-17.
What interventions are being tested in trial NCT04699812?
The interventions under investigation include: ELECTROCARDIOGRAM (ECG) PATCH WEAR (DEVICE).
Who is sponsoring clinical trial NCT04699812?
This trial is sponsored by Apple, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04699812's enrollment target sits among peer trials
573 179th of 2000 higher than 1,822 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05977751 · 573 participants · NA
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
- NCT07349537 · 574 participants · Phase 1
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- NCT05131022 · 572 participants · Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- NCT06346392 · 572 participants · Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI